Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metreleptin - Amryt Pharma

Next Previous
Drug Profile

Metreleptin - Amryt Pharma

Alternative Names: Human recombinant methionyl leptin; Methionyl human leptin; Myalept; MYALEPTA; r-metHuLeptin; Recombinant methionyl human leptin

Latest Information Update: 14 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Amryt Pharma; Beth Israel Deaconess Medical Center; Shionogi; University of Texas Southwestern Medical Center
  • Class Adipokines; Antihyperglycaemics; Obesity therapies; Recombinant proteins
  • Mechanism of Action Leptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lipodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Congenital generalised lipodystrophy
  • Phase III Familial partial lipodystrophy
  • Phase II Amenorrhoea
  • Phase I Lipomatosis
  • No development reported Lipodystrophy; Type 1 diabetes mellitus

Most Recent Events

  • 14 Oct 2024 Phase-III clinical trials in Familial partial lipodystrophy (In adolescents, In adults, In the elderly) in USA (SC) (NCT06679270)
  • 16 Jul 2024 Amryt Pharma initiates a phase IIb trial for Congenital generalised lipodystrophy (In children) in Belgium and Italy (NCT06502990)
  • 05 Feb 2024 Registered for Congenital generalised lipodystrophy (In adults, In adolescents, In children) in Canada (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top